vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and Orchid Island Capital, Inc. (ORC). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $38.5M, roughly 1.2× Orchid Island Capital, Inc.). Orchid Island Capital, Inc. runs the higher net margin — 268.7% vs -4.8%, a 273.5% gap on every dollar of revenue. On growth, Orchid Island Capital, Inc. posted the faster year-over-year revenue change (372.6% vs -47.3%). Over the past eight quarters, Orchid Island Capital, Inc.'s revenue compounded faster (301.6% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.
IRWD vs ORC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $38.5M |
| Net Profit | $-2.3M | $103.4M |
| Gross Margin | — | — |
| Operating Margin | 14.3% | — |
| Net Margin | -4.8% | 268.7% |
| Revenue YoY | -47.3% | 372.6% |
| Net Profit YoY | -200.9% | 1764.9% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.7M | $38.5M | ||
| Q3 25 | $122.1M | $26.9M | ||
| Q2 25 | $85.2M | $23.2M | ||
| Q1 25 | $41.1M | $19.7M | ||
| Q4 24 | $90.5M | — | ||
| Q3 24 | $91.6M | $340.0K | ||
| Q2 24 | $94.4M | $-697.0K | ||
| Q1 24 | $74.9M | $-2.5M |
| Q4 25 | $-2.3M | $103.4M | ||
| Q3 25 | $40.1M | $72.1M | ||
| Q2 25 | $23.6M | $-33.6M | ||
| Q1 25 | $-37.4M | $17.1M | ||
| Q4 24 | $2.3M | — | ||
| Q3 24 | $3.6M | $17.3M | ||
| Q2 24 | $-860.0K | $-5.0M | ||
| Q1 24 | $-4.2M | $19.8M |
| Q4 25 | 14.3% | — | ||
| Q3 25 | 61.8% | — | ||
| Q2 25 | 53.2% | — | ||
| Q1 25 | -70.7% | — | ||
| Q4 24 | 34.8% | — | ||
| Q3 24 | 28.0% | — | ||
| Q2 24 | 26.5% | — | ||
| Q1 24 | 14.7% | — |
| Q4 25 | -4.8% | 268.7% | ||
| Q3 25 | 32.8% | 267.8% | ||
| Q2 25 | 27.7% | -145.0% | ||
| Q1 25 | -90.9% | 86.9% | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 4.0% | 5094.1% | ||
| Q2 24 | -0.9% | 714.3% | ||
| Q1 24 | -5.6% | -794.2% |
| Q4 25 | $0.01 | — | ||
| Q3 25 | $0.23 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $-0.23 | — | ||
| Q4 24 | $0.03 | — | ||
| Q3 24 | $0.02 | — | ||
| Q2 24 | $-0.01 | — | ||
| Q1 24 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $665.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-261.8M | $1.4B |
| Total Assets | $396.9M | $11.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $215.5M | $665.9M | ||
| Q3 25 | $140.4M | $583.9M | ||
| Q2 25 | $92.9M | $440.8M | ||
| Q1 25 | $108.5M | $396.4M | ||
| Q4 24 | $88.6M | — | ||
| Q3 24 | $88.2M | $322.1M | ||
| Q2 24 | $105.5M | $241.0M | ||
| Q1 24 | $121.5M | $190.4M |
| Q4 25 | — | — | ||
| Q3 25 | $199.5M | — | ||
| Q2 25 | $199.3M | — | ||
| Q1 25 | $199.2M | — | ||
| Q4 24 | $199.0M | — | ||
| Q3 24 | $198.8M | — | ||
| Q2 24 | $198.6M | — | ||
| Q1 24 | $398.3M | — |
| Q4 25 | $-261.8M | $1.4B | ||
| Q3 25 | $-264.2M | $1.1B | ||
| Q2 25 | $-308.2M | $912.0M | ||
| Q1 25 | $-334.1M | $855.9M | ||
| Q4 24 | $-301.3M | — | ||
| Q3 24 | $-311.3M | $656.0M | ||
| Q2 24 | $-321.7M | $555.9M | ||
| Q1 24 | $-330.5M | $481.6M |
| Q4 25 | $396.9M | $11.7B | ||
| Q3 25 | $396.1M | $9.1B | ||
| Q2 25 | $342.9M | $7.6B | ||
| Q1 25 | $327.2M | $7.3B | ||
| Q4 24 | $350.9M | — | ||
| Q3 24 | $389.5M | $5.9B | ||
| Q2 24 | $395.6M | $4.9B | ||
| Q1 24 | $438.8M | $4.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | $120.4M |
| Free Cash FlowOCF − Capex | $74.6M | — |
| FCF MarginFCF / Revenue | 156.3% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 1.16× |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $120.4M | ||
| Q3 25 | $47.6M | $28.0M | ||
| Q2 25 | $-15.1M | $18.4M | ||
| Q1 25 | $20.0M | $25.8M | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $9.9M | $-14.8M | ||
| Q2 24 | $33.5M | $19.3M | ||
| Q1 24 | $45.0M | $45.0M |
| Q4 25 | $74.6M | — | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $-15.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.9M | — | ||
| Q2 24 | $33.4M | — | ||
| Q1 24 | $44.9M | — |
| Q4 25 | 156.3% | — | ||
| Q3 25 | 39.0% | — | ||
| Q2 25 | -17.7% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 35.4% | — | ||
| Q1 24 | 60.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 1.16× | ||
| Q3 25 | 1.19× | 0.39× | ||
| Q2 25 | -0.64× | — | ||
| Q1 25 | — | 1.51× | ||
| Q4 24 | 6.74× | — | ||
| Q3 24 | 2.71× | -0.86× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
